GlassScriptPhysician profile
Frank J Mccabe
NPI 1003870973
$1,197.01
in general payments reported to CMS, 2019-2025
13 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $45.56 · 2021: $136 · 2022: $87.75 · 2023: $241 · 2024: $278 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.75 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $371.16 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $321.18 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $145.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $123.60 | 2019-2021 | |
| Astellas Pharma US INC | $97.53 | 2024-2025 | Izervay |
| Vertos Medical, INC. | $33.53 | 2023 | Mild Device Kit |
| Apellis Pharmaceuticals, INC. | $33.20 | 2022-2024 | Syfovre |
| Biogen, INC. | $26.81 | 2023 | |
| Harrow Eye, LLC | $25.81 | 2024 | Iheezo |
| Alimera Sciences, INC. | $18.42 | 2023 | Iluvien |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.